Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Gains from Sales and Divestitures (2019 - 2025)

Eton Pharmaceuticals' Gains from Sales and Divestitures history spans 6 years, with the latest figure at $84204.0 for Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures fell 6.86% year-over-year to $84204.0; the TTM value through Sep 2025 reached $84204.0, down 6.86%, while the annual FY2024 figure was $90402.0, 1.09% down from the prior year.
  • Gains from Sales and Divestitures for Q3 2025 was $84204.0 at Eton Pharmaceuticals, up from $889.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $91402.0 in Q3 2023 and bottomed at $889.0 in Q2 2025.
  • The 4-year median for Gains from Sales and Divestitures is $90402.0 (2024), against an average of $65185.1.
  • The largest annual shift saw Gains from Sales and Divestitures changed 0.0% in 2021 before it fell 6.86% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $7595.0 in 2021, then skyrocketed by 1103.45% to $91402.0 in 2023, then dropped by 1.09% to $90402.0 in 2024, then dropped by 6.86% to $84204.0 in 2025.
  • Per Business Quant, the three most recent readings for ETON's Gains from Sales and Divestitures are $84204.0 (Q3 2025), $889.0 (Q2 2025), and $90402.0 (Q4 2024).